INCY Stock Recent News
INCY LATEST HEADLINES
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%.
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.
The allure of penny stocks is understandable. For literally just a few dollars, you can control hundreds, if not thousands, of shares.
The global oncology ecosystem is at a pivotal juncture. Significant advancements in discovery, development, and delivery of novel cancer treatments are enhancing patient outcomes.
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.